The reference number of our hospital is12t-941125.

Name of invention: Monoclonal antibody against polyethylene glycol (E 1 1)

Creators: Luo Fulun, Chen Bingmei, Zheng Tianlu and Lin Zhihong (Academia Sinica, Kaohsiung Medical University).

Patent number: NA

abstract:

Modification of polyethylene glycol into drugs, protein, nanoparticles or liposomes has been widely proved to improve the biological activity and safety of molecules, and has been approved by the US Food and Drug Administration for human body. Therefore, the qualitative and quantitative modification of PEG-modified molecules will be very important for the clinical development and application of these molecules. The present invention (E 1 1) is an antibody that can specifically bind to polyethylene glycol repeating unit (CH2CH2O), which can not only remove polyethylene glycol modified molecules in vivo, but also detect polyethylene glycol molecules and any polyethylene glycol modified molecules by western dot blot, enzyme immunoassay and flow cytometry, and the detection sensitivity increases with the increase of the length and number of polyethylene glycol. More importantly, combined with another anti-PEG AGP3 antibody we developed before, we can successfully establish an enzyme immunoassay method for sandwiches. Even under the condition of containing 65,438+00% fetal bovine serum, we can quantitatively determine PEG free molecules, PEG-modified protein or nano-fluorescent particles, and even PEG-modified liposomes, and the sensitivity reaches the level of Nike (ng), so E 165438.

Possible application scope:

● Engaged in research institutions and biotechnology industries of therapeutic molecules modified by polyethylene glycol (PEG).

● Engaged in research institutions and biotechnology industry of polyethylene glycol modified nanoparticles.

● Research institutions and biotechnology industries engaged in the qualitative and quantitative analysis of biomolecules.

The invention has the advantages that:

There is no simple method to measure the concentration of PEG-modified protein in vivo and in vitro. At present, PEG antibody can be qualitative and quantitative. Except for the first generation of AGP3/IgM monoclonal antibody we developed before, there is no report about anti-PEG monoclonal antibody. The second generation monoclonal antibody E 1 1 is IgG 1, which has a small molecular weight and a good efficiency in removing polyethylene glycol modified molecules in vivo. It can also detect polyethylene glycol molecules and any molecules modified by polyethylene glycol by protein blot, enzyme immunoassay and flow cytometry. Combined with another anti-PEG AGP3 antibody we developed before, we can successfully establish an enzyme immunoassay method for sandwiches, even if it contains 65438+.

reference data

http://otl.sinica.edu.tw/index.php? t = 9 & amp； group _ id = 20 & amparticle_id=508

Academia Sinica

R&D achievements

reference data

http://polymer.che.ncku.edu.tw/papers/G-Blends/G082.pdf

Removal of polyethylene glycol

This is a paper.